Saccharomyces Boulardii for H. Pylori Support

Research suggests that Saccharomyces boulardii may serve as a useful adjunct to standard H. pylori eradication therapy, with a 2025 meta-analysis of 11 randomized controlled trials finding that adding S. boulardii to bismuth-containing quadruple antibiotic regimens improved eradication rates and reduced side effects such as diarrhea compared to standard treatment alone. A broader 2010 meta-analysis covering over 5,000 patients across 27 trials similarly found promising signals for S. boulardii in reducing H. pylori treatment-related side effects, and a 2016 review noted that while evidence for probiotics in H. pylori infection is emerging, identifying the most effective strains and protocols requires further investigation. Several reviews caution that probiotic evidence is highly strain- and condition-specific, meaning findings for S. boulardii in one context cannot be generalized to all probiotic products or all uses, and that long-term safety data remain limited, particularly for individuals with serious underlying health conditions. Overall, the available evidence — drawn from randomized controlled trials, meta-analyses, and systematic reviews — leans supportive for S. boulardii as a complement to conventional H. pylori therapy, though researchers and reviewers consistently note that more targeted research is needed before firm conclusions can be drawn.